CD34+ Product
Organ Transplant Rejection (Immune Tolerance)
Phase 1Active
Key Facts
About Ossium Health
Ossium Health is pioneering a new paradigm in cell therapy by sourcing hematopoietic stem cells from deceased donors, a scalable and ethically distinct alternative to traditional bone marrow donation. The company has advanced its lead programs into clinical studies, with initial patients treated for transplant-related indications and orthopedics, and has secured significant partnerships with entities like NMDP and BARDA. Backed by over $125 million in venture funding from investors like First Round Capital, Vivo Capital, and General Catalyst, Ossium is positioned to address critical shortages in transplant medicine and expand into broader therapeutic areas.
View full company profile